EUCTR2019-002425-30-PLActive, not recruitingPhase 1
A Phase 3, 182-week, Open-Label, Extension Study to Investigate the Safety and Tolerability Study of TD-9855 in Treating Symptomatic Neurogenic Orthostatic Hypotension (symptomatic nOH) in Subjects with Primary Autonomic Failure
Theravance Biopharma Ireland Limited0 sites84 target enrollmentStarted: January 13, 2020Last updated:
Trial Snapshot
- Phase
- Phase 1
- Status
- Active, not recruiting
- Enrollment
- 84
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional clinical trial of medicinal product
Eligibility Criteria
- Sex
- All
Inclusion Criteria
- •1. Completion of Study 0170 and, in the opinion of the Investigator, would benefit from long-term treatment with TD-9855.
- •2. The subject must be able to understand the nature of the study and must provide written informed consent prior to the conduct of any study procedures (including any changes occurring in the subject’s current therapeutic regimen).
- •3. The subject must be willing to continue on treatment and must continue to meet all the inclusion criteria for the preceding study (Study 0170) except, a score of =4 in OHSA#1.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 71
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 49
Exclusion Criteria
- •1. Subjects may not be enrolled in another clinical trial, with the exception of purely observational studies, which are allowed.
- •2. Psychiatric, neurological, or behavioral disorders that may interfere with the ability of subjects to give informed consent, or interfere with the conduct of the study.
- •3. Medical, laboratory, or surgical issues deemed by the Investigator to be clinically significant.
- •4. Hypersensitivity to TD-9855 or the formulation excipients.
Investigators
Similar Trials
Active, not recruiting
Phase 1
A Phase 3, 182-week, Open-Label, Extension Study to Investigate the Safety and Tolerability of TD-9855 in Treating Symptomatic Neurogenic Orthostatic Hypotension (symptomatic nOH) in Subjects with Primary Autonomic FailureSymptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic FailureEUCTR2019-002425-30-DKTheravance Biopharma Ireland Limited120
Active, not recruiting
Phase 1
Phase 3 Open-Label Extension Study of TD-9855 for Treating symptomatic nOH in Subjects with Primary Autonomic FailureSymptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic FailureEUCTR2019-002425-30-DETheravance Biopharma Ireland Limited120
Active, not recruiting
Phase 1
Phase 3 Open-Label Extension Study of TD-9855 for Treating symptomaticnOH in Subjects with Primary Autonomic FailureSymptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic FailureEUCTR2019-002425-30-GBTheravance Biopharma Ireland Limited120
Active, not recruiting
Phase 1
Phase 3 Open-Label Extension Study of TD-9855 for Treating symptomaticnOH in Subjects with Primary Autonomic FailureSymptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic FailureEUCTR2019-002425-30-PTTheravance Biopharma Ireland Limited110
Active, not recruiting
Phase 1
Phase 3 Open-Label Extension Study of TD-9855 for Treating symptomaticnOH in Subjects with Primary Autonomic FailureEUCTR2019-002425-30-ATTheravance Biopharma Ireland Limited120